Company Description
Quantum BioPharma Ltd., a biopharmaceutical company, researches and develops a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development.
The company operates through two segments, Biopharmaceutical and Strategic Investments. Its lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models.
The company is also developing a treatment for alcohol misuse for application in hospitals and other medical practices.
In addition, it maintains a portfolio of strategic investments comprising loans secured by residential property.
The company was formerly known as FSD Pharma Inc. and changed its name to Quantum BioPharma Ltd., in August 2024.
Quantum BioPharma Ltd., is headquartered in Toronto, Canada.
| Country | Canada |
| Founded | 1998 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 17 |
| CEO | Zeeshan Saeed |
Contact Details
Address: 55 University Ave., Suite 1003 Toronto, ON M5J 2H7 Canada | |
| Website | fsdpharma.com |
Stock Details
| Ticker Symbol | QNTM |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001771885 |
| ISIN Number | CA74764Y2050 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Lakshmi P. Kotra BPHARM, Ph.D. | Chief Executive Officer of Lucid and Director |
| Zeeshan Saeed | Founder, Chief Executive Officer, President and Executive Co-Chairman |
| Anthony John Durkacz | Founder and Executive Co-Chairman |
| Donal Carroll CPA | Chief Financial Officer and Chief Operating Officer |
| Nathan Coyle CPA | Controller |
| Jason D. Sawyer | Head of Finance and Mergers and Acquisitions |
| Maryann Adesso | Corporate Secretary |
| Randell Mack | President of FSD BioSciences |
| Dr. Andrzej Chruscinski M.D., Ph.D. | Vice President of Clinical and Scientific Affairs of Lucid |
| Kevin Cassidy | Vice President of Quality-Lucid |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 12, 2024 | 6-K | Report of foreign issuer |
| Oct 29, 2024 | 6-K | Report of foreign issuer |
| Oct 22, 2024 | 6-K | Report of foreign issuer |
| Oct 21, 2024 | 6-K | Report of foreign issuer |
| Oct 7, 2024 | 6-K | Report of foreign issuer |
| Sep 30, 2024 | 6-K | Report of foreign issuer |
| Sep 16, 2024 | 6-K | Report of foreign issuer |
| Sep 9, 2024 | 6-K | Report of foreign issuer |
| Sep 9, 2024 | 6-K | Report of foreign issuer |
| Aug 30, 2024 | 6-K | Report of foreign issuer |